Teekay (NYSE: TK) director plans sale of 2,581 NYSE shares

Teekay Corporation (TK) reported Q2 2026 GAAP net income of $226 million ($6.49/share) including a $32.3 million gain from selling a Suezmax vessel. Adjusted net income was $194 million ($5.56/share), up 50% vs. the prior quarter. The company generated $200 million in free cash flow, ended with $1.2 billion cash and zero debt, and committed $190 million for two Suezmax newbuildings.

Teekay Corporation reported Q2 net income attributable to shareholders of $69.5M, or 79 cents/share, vs $18.7M, or 22 cents/share, a year earlier. Revenue rose to $379.1M from $232.2M and operating income to $220.8M from $52.7M, driven by Teekay Tankers’ record spot tanker rates amid Middle East disruptions. Suezmax averaged $109,200/day and Aframax/LR2 $74,100/day. Teekay Tankers booked newbuilds for $190M and sold vessels, adding gains.

TEEKAY CORP LTD (TK) furnished an SEC Form 6-K — earnings release. Item 1 — Information Contained in this Form 6-K Report Attached as Exhibit 1 is a copy of an announcement of Teekay Corporation Ltd. dated July 29, 2026. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to b

Teekay Corp.’s (NYSE:TK) shares opened lower Tuesday after closing at $13.34 and gapping down to $12.38; the stock last traded at $12.50. Wall Street Zen downgraded TK from buy to hold, according to MarketBeat. Teekay reported $0.55 EPS on May 13 and announced a $1.00 special dividend payable June 2.

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.